Francisco J. Esteva

YouTube video by Cancer Treatment Updates Why More People Are Surviving Cancer in 2026

Numbers matter, but people matter more. This video highlights the 2026 ACS cancer data — I explain how these trends show up in the clinic and what they mean for patients and caregivers.
youtu.be/Ba4HFqmLICo

YouTube video by Cancer Treatment Updates SABCS 2025 Recap: Breast Cancer Updates for 2026

An honest conversation with Victoria Goldberg—breast cancer patient and host of the LiveFromStage4 Podcast—about living with stage IV disease.
Now on YouTube.

youtube.com/watch?v=Z_5Y...

Honored to be recognized by ScholarGPS for lifetime contributions to trastuzumab research. HER2-targeted therapy has changed outcomes for patients with breast cancer worldwide. This progress belongs to patients, collaborators, and generations of scientists.

Onward.

scholargps.com

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer | NEJM Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or pro...

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

YouTube video by Cancer Treatment Updates Should You Get Tested for Breast Cancer Genes?

🧬 Not everyone with breast cancer—or a family history—actually needs genetic testing. The real question is: how do you know if it’s the right step for you?

Take a look—you might be surprised by who doesn’t need testing, and who definitely should.

youtu.be/ctQZ8Fd7AAE?...

YouTube video by Cancer Treatment Updates Fighting Cancer with Clarity & Hope | An Oncologist's Guide

Cancer is overwhelming. But good information can change everything.

Each week, I share short, evidence-based videos on YouTube—breaking down the latest in treatment trends, side effect relief, and survivorship care.

youtu.be/vcetk3Ixiv0

#cancer #bcsm @ascopost.bsky.social @ascocancer.bsky.social

#ASCO25 trials suggest carboplatin may be safely omitted from neoadjuvant therapy in many HER2+ early breast cancers. neoCARHP showed non-inferior pCR without carboplatin and fewer side effects. CompassHER2-pCR confirmed strong THP efficacy, especially in ER− tumors.
#bcsm @ascocancer.bsky.social

Are serial liquid biopsies finally ready for prime time?

If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.

That means #ctDNA won’t just monitor—it could guide treatment.

@ascocancer.bsky.social
#bcsm

New hope for hormone-resistant breast cancer?
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯

@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social

@bsky.app more than adequately picked up what was lost from Twitter when it comes to medical conferences.
#sabcs24 was a throwback to those old days of following posts, seeing different perspectives on data, and seeing colleagues in San Antonio.
#hcsm has a new home. #oncsm #oncsky

Just returned from #SABCS24—what an incredible experience! It was great reconnecting with old friends, making new connections, and immersing myself in the latest breakthroughs in breast cancer research and treatment. Events like this remind me how collaboration drives progress.